Tuesday, January 16, 2018 -- Lab studies show promise for a clinical trial aimed at improving current immune therapies
Tuesday, January 16, 2018 -- Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma.
Thursday, January 11, 2018 -- Desmoplastic melanoma is a rare subtype of melanoma that is commonly found on sun-exposed areas, such as the head and neck, and usually seen in older patients.
Friday, January 12, 2018 -- Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Thursday, January 11, 2018 -- Skin cancer is the most common cancer in the United States, and nonmelanoma skin cancer is the most common type of skin cancer, affecting more than 3 million Americans every year.
Tuesday, January 16, 2018 -- Purpose: New targets are required for the control of advanced metastatic disease. We investigated the use of cadherin RGD motifs, which activate the α2β1integrin pathway, as targets for the development of therapeutic monoclonal antibodies (mAb). Experimental Design: Cadherin 17 (CDH17) fragments and peptides were prepared and used for immunization and antibody development. Antibodies were tested for inhibition of β1 integrin and cell adhesion, proliferation, and invasion assays using cell lines from different cancer types (colorectal, pancreatic, melanoma, and breast cancer). Effects of the mAbs on cell signaling were determined by Western blot analysis. Nude mice were used for survival analysis after treatment with RGD-specific mAbs and metastasis development. Results: Antibodies against full-length CDH17 failed to block the binding to
Friday, January 12, 2018 -- Researchers from the Moffitt Cancer Center maintain drugs that reactivate the immune system are beneficial to desmoplastic melanoma patients. The study, published in Nature, revealed patients are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed. Drugs reactivating a patient’s … Read More » The post Immune-activating treatments aid desmoplastic melanoma appeared first on Life Science Daily.
Tuesday, January 16, 2018 -- UCLA study findings revealed two-thirds of desmoplastic melanoma patients responded positively when immunotherapy treatment was administered. Details of the probe published in Nature outlined the evaluation of 60 people with advanced desmoplastic melanoma who received anti-PD-1 or anti-PD-L1 therapies over … Read More » The post Immunotherapy effective versus desmoplastic melanoma appeared first on Life Science Daily.